Irvine, CA – Feb. 12, 2025 – Johnson & Johnson MedTech, an emerging leader in neurovascular care, announced today the launch of the CEREGLIDE™ 92 Catheter System, a next-generation .092” catheter with the INNERGLIDE™ 9 delivery aid, indicated for use in facilitating the insertion and guidance of interventional devices in the neurovascular system. CEREGLIDE™ 92 is a .092" inner diameter catheter system that allows physicians to achieve large distal access and is designed to provide flow reduction in the M1i when inserting devices for the revascularization of patients with acute ischemic strokeii. The larger lumen also provides distal support for multiple neurovascular tools when treating aneurysms and other hemorrhagic complicationsiii. CEREGLIDE™ 92 is the latest catheter in Johnson & Johnson MedTech’s growing catheter portfolio designed to integrate with Stroke Solutions, such as CEREGLIDE™ 71, PROWLER™ EX and EMBOTRAP™ III1,iv.
Acute ischemic strokes account for 85% of all strokes worldwide and the M1 territory is the most commonly affected by stroke. By utilizing CEREGLIDE 92 to insert aspiration catheters during thrombectomy procedures, physicians can restore blood flow in the brain by directly withdrawing a blood clot, or inserting a catheter in combination with a stent retriever2. While more than half of ischemic stroke patients treated with mechanical thrombectomy regain functional independence, some patients are left untreated or suffer poor outcomes due to access challenges and failures in navigating the complex anatomy of the brain2.
CEREGLIDE™ 92 features design elements including the co-packaged INNERGLIDE™ 9 Delivery Aid, a .092” inner diameter, full catheter visibility with BRITE-LINE™ Technologyv, and TruCourse™ Technology, which increases distal tip flexibility aiding in catheter trackabilityvi,vii. The system tracks to the M1viii and provides large distal placement for procedural control along with full catheter visibility under fluoroscopyv.
“Vessel tortuosity and other anatomical challenges are present in approximately 50 percent of mechanical thrombectomy cases, which can increase procedure time or prevent ability to treat,” said Dr. Brian Jankowitz, Chief of Neurosurgery and Co-Chair of the Stroke and Neurovascular Program at the Hackensack Meridian Neuroscience Institute at JFK University Medical Centerix. “As an early user of CEREGLIDE™ 92 and INNERGLIDE™ 9, this super large-bore catheter system helps provide quick and seamless access to the M1 with the benefit of flow control, allowing us to rapidly reperfuse the patient and extend the benefits of next generation stroke technology to more patients.”
Devices within Johnson & Johnson MedTech’s Neurovascular portfolio are developed using expert stroke science insights from the Neuro Thromboembolic Initiative (NTI). The result is devices that have been tested in models that recreate real-world scenarios and seek to further address clinical unmet need.
“Johnson & Johnson MedTech is continuing to innovate to help address the access challenges physicians face during mechanical thrombectomy procedures with the launch of CEREGLIDE™ 92,” said Mark Dickinson, Worldwide President, Neurovascular, Johnson & Johnson MedTech. “The CEREGLIDE™ 92 Catheter System is the latest innovation in our CEREGLIDE and ischemic stroke suite of technologies designed to assist physicians in treating their patients and maximizing procedural outcomes, to ultimately change the trajectory of stroke.”
As part of ongoing sustainability efforts, the CEREGLIDE™ 92 Catheter System will utilize electronic instructions for use (e-IFUs). E-IFUs are expected to help reduce Johnson & Johnson MedTech’s environmental footprint, lower CO2 emissions caused during shipment and facilitate a reduction in healthcare systems’ post-consumer recycling and medical waste disposal.
The CEREGLIDE™ 92 Catheter System is now commercially available in the U.S. For more information visit https://www.jnjmedtech.com/en-US/product/cereglide-92-catheter-system-trucourse.
Cardiovascular Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more information, visit https://www.jnjmedtech.com/en-US/companies/cerenovus and connect on LinkedIn and X.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopaedics, surgery and vision solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn. DePuy Synthes Sales, Inc. d/b/a CERENOVUS and Medical Device Business Services, Inc. are part of Johnson & Johnson MedTech.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the CEREGLIDE™ 92 catheter. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes Sales, Inc. d/b/a CERENOVUS, Medical Device Business Services, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K , including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither DePuy Synthes Sales, Inc. d/b/a CERENOVUS, Medical Device Business Services, Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
US_NEU_ISCH_395556
Footnotes
i Based on catheter OD, average size of M1 vessel, and published literature.
ii Calculation between published OD and ID parameters compared to Zoom 88 LDP, Sofia 88, Millipede 088. AS of April 28, 2024, Distal delivery refers to the M1.
iii Compared to published ID parameters of Zoom 88 LDP, Sofia 88, Millipede 088 as of April 24, 2024.
iv Based on physician evaluation in a clinically relevant silicone flow model.
v Physician evaluation in a silicone flow model under fluoroscopy. BRITE-LINE™ is a proprietary technology which enables full length visibility of the catheter.
vi Physician evaluation in a silicone flow model under fluoroscopy. BRITE-LINE™ is a proprietary technology which enables full length visibility of the catheter
vii TruCourse™ is a proprietary technology used to increase flexibility of the device.
viii More trackable than Zoom 88, based on physician evaluation in a clinically relevant silicone flow model. Success determined by navigation to the target site.
ix Dr. Brian Jankowitz is a lead investigator for SPLENDID and was not compensated for his contributions to this announcement
1 Verification & Validation - Flash 9 (CEREGLIDE 92) Design Validation Physician Report. Rev A. March 3, 2023, ThingWorx #501219542
2 Penide, J., Mirza, M., McCarthy, R.et al. Systematic Review on Endovascular Access to Intracranial Arteries for Mechanical Thrombectomy in Acute Ischemic Stroke.Clin Neuroradiol32,5–12 (2022). https://doi.org/10.1007/s00062-021-01100-7
Media contact:
Kristina Kauffman
KKauffman4@its.jnj.com